Buck Institute and Insilico Medicine form aging research collaboration
Buck Institute, the first independent biomedical research institute focused solely on aging, has formed a research collaboration with Insilico Medicine and a third unnamed institution.
Buck Institute, the first independent biomedical research institute focused solely on aging, has formed a research collaboration with Insilico Medicine and a third institution not named in the available text. Insilico applies generative adversarial networks (GANs) and reinforcement learning (RL) to target discovery and molecule generation. Alex Zhavoronkov pioneered applying GANs and RL to drug discovery in 2016.
Specifics (targets, timelines, funding) are not disclosed in the press release.
Insilico entered the Eternal Search company rankings this week: #24 (15.4). Zhavoronkov is #4 among heroes (42.0).
Open the related Eternal Search page
Sources
Three leaders in longevity biotechnology form a research collaboration
AI Meets Aging Inside the Longevity Revolution with Insilico ...
A formal research collaboration between the oldest independent geroscience institute and an AI drug discovery company with clinical-stage assets is a concrete institutional signal. Eternal Search tracks both parties: Insilico entered the company rankings this week at #24 (15.4), Zhavoronkov is #4 among heroes (42.0), and Buck Institute has an organization profile the reader can inspect directly.